{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["gemcitabine","docetaxel"]],"indication":"BCG-naïve non-muscle invasive urothelial carcinoma of the bladder","name":"GEMDOCE","nct_id":"NCT04386746","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=gemdoce-nct04386746. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"GEMDOCE","arms":[{"description":"Gemcitabine/Docetaxel induction is given intravesically in sequential order once a week for six consecutive weeks. One gram of gemcitabine in 50 ml of sterile water is slowly instilled into the bladder via a Foley catheter and the catheter is clamped for 60 minutes. The bladder is then drained and 40 mg of docetaxel in 50 ml of NSS is then slowly instilled via the Foley catheter into the bladder. The catheter is again clamped for 60 minutes before draining. If initial efficacy seen, patients will have monthly maintenance instillations of Gemcitabine/Docetaxel.","label":"Intravesical Gemcitabine/Docetaxel","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-11-30","type":"ESTIMATED"},"conditions":["Urothelial Carcinoma Bladder","Bladder Cancer"],"enrollment":{"count":27,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Gemcitabine","otherNames":["Gemzar"],"type":"DRUG"},{"name":"Docetaxel","otherNames":["Taxotere"],"type":"DRUG"}],"last_update":"2025-11-17","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","official_title":"A Phase II Trial for the Use of Intravesical Gemcitabine and Docetaxel (GEMDOCE) in the Treatment of BCG naïve Non-muscle Invasive Urothelial Carcinoma of the Bladder","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2022-10-04","type":"ACTUAL"},"primary_outcomes":[{"measure":"3-Month Complete Response Rate","timeFrame":"3 months"}],"references":[],"start_date":{"date":"2020-07-29","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer","url":"https://clinicaltrials.gov/study/NCT04386746"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/gemdoce-nct04386746"}